سعر لوبيستون 8 ميكروجرام 20 قرص 2026

Lubistone 8 mcg capsules (lubiprostone), 20 capsules per pack, by Medizen for Pharmaceutical Industries / Alwady Pharmaceutical Co. (ALPAC), Egypt. Lubiprostone is a locally acting ClC-2 chloride channel activator used for chronic constipation; in the US the 8 mcg strength is the dose used for IBS with constipation.

• Chronic idiopathic constipation (CIC) in adultsPopulation: AdultsDailyMed (US National Library of Medicine)
• Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dose escalation; effectiveness with diphenylheptane opioids (e.g. methadone) not establishedPopulation: AdultsDailyMed (US National Library of Medicine)
• Irritable bowel syndrome with constipation (IBS-C) in women 18 years and older (8 mcg twice daily)Population: Women ≥18 yearsDailyMed (US National Library of Medicine)

• Most common in CIC trials: nausea, diarrhoea, headache, abdominal pain, abdominal distension and flatulence.International label, same formulation · DailyMed (US National Library of Medicine)

• Known or suspected mechanical gastrointestinal obstruction.International label, same formulation · DailyMed (US National Library of Medicine)

• Nausea (taking with food may reduce it); diarrhoea (avoid in severe diarrhoea, stop if severe diarrhoea occurs); syncope and hypotension (mostly with 24 mcg twice daily, sometimes within an hour of a dose); dyspnoea (chest tightness, usually within 30-60 minutes of the first dose); evaluate for bowel obstruction before starting therapy.International label, same formulation · DailyMed (US National Library of Medicine)

• Diphenylheptane opioids (e.g. methadone)Methadone and other diphenylheptane opioids dose-dependently reduce ClC-2 activation by lubiprostone in nonclinical studies; possible dose-dependent loss of efficacy; no in vivo interaction studies.DailyMed (US National Library of Medicine)

• Limited human data are insufficient to inform a drug-associated risk of adverse developmental outcomes; animal studies showed no increase in structural malformations, but dose-dependent fetal loss occurred in guinea pigs.International label, same formulation · DailyMed (US National Library of Medicine)
• No data on presence in human milk; neither lubiprostone nor its active metabolite M3 was found in rat milk; monitor breastfed infants for diarrhoea.International label, same formulation · DailyMed (US National Library of Medicine)

• Lubiprostone: Locally acting activator of ClC-2 chloride channels on the apical membrane of the intestinal epithelium; increases chloride-rich intestinal fluid secretion and motility without altering serum sodium and potassium (US label).